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Abstract: Onset of genetically determined neurodegenerative
diseases is difﬁcult to specify because of their insidious and
slowly progressive nature. This is especially true for spino-
cerebellar ataxia (SCA) because of varying affection of many
parts of the nervous system and huge variability of symp-
toms. We investigated early symptoms in 287 patients with
SCA1, SCA2, SCA3, or SCA6 and calculated the inﬂuence
of CAG repeat length on age of onset depending on (1) the
deﬁnition of disease onset, (2) people deﬁning onset, and (3)
duration of symptoms. Gait difﬁculty was the initial symptom
in two-thirds of patients. Double vision, dysarthria, impaired
hand writing, and episodic vertigo preceded ataxia in 4% of
patients, respectively. Frequency of other early symptoms did
not differ from controls and was regarded unspeciﬁc. Data
about disease onset varied between patients and relatives for
1 year or more in 44% of cases. Inﬂuence of repeat length
on age of onset was maximum when onset was deﬁned as
beginning of permanent gait disturbance and cases with
symptoms for more than 10 years were excluded. Under
these conditions, CAG repeat length determined 64% of
onset variability in SCA1, 67% in SCA2, 46% in SCA3, and
41% in SCA6 demonstrating substantial inﬂuence of nonrep-
eat factors on disease onset in all SCA subtypes. Identiﬁca-
tion of these factors is of interest as potential targets for
disease modifying compounds. In this respect, recognition of
early symptoms that develop before onset of ataxia is manda-
tory to determine the shift from presymptomatic to affected
status in SCA.  2008 Movement Disorder Society
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Spinocerebellar ataxia (SCA) comprises a group of
neurodegenerative multisystem disorders, which present
with progressive ataxia as their key feature. It is caused
by mutations in more than 25 genes of which 14 have
been cloned so far.1–3 The expansion of a CAG trinucleo-
tide repeat in the coding region of the respective gene
causes the disease in seven subtypes including the most
prevalent genotypes in Europe (SCA1, SCA2, SCA3,
and SCA6). SCA is a phenotypically heterogeneous in-
sidious disease characterized by slowly progressive gait
ataxia and variable additional symptoms including visual
problems, dysarthria, dysphagia, limb ataxia, spasticity,
Parkinsonism, dystonia, peripheral neuropathy, restless
legs syndrome, and urge incontinence. Because of its he-
reditary nature, the pathogenic process is likely to start
early in life or even prior to birth, but early development
is generally normal and often patients remain clinically
healthy far beyond the second, third, or even seventh
decade of their life. The exact disease onset, however, of-
ten remains unclear and has only rarely been well deﬁned
in previous studies. Determination of disease onset might
differ whether patients are asked for onset of gait ataxia
or, alternatively, for onset of any other kind of behavioral
or neurological problem. Moreover, it might vary
depending on the person that is asked—either the patient
or his/her relatives. Despite lack of standardization in the
assessment of age at onset, signiﬁcant correlations have
been found between the age of onset and the number of
the CAG motifs in the expanded allele in all of the more
common SCA subtypes (SCA1, SCA2, SCA3, and
SCA6) and repeat length can account for 50 to 80% of
variability in age of onset,4–10 it still remains unknown to
what extend differences in the ascertainment of disease
onset contribute to the unexplained portions of variabi-
lity. Apart from CAG repeat expansions, alternative
genetic or environmental factors inﬂuencing age of onset
in SCA have rarely been identiﬁed11–13—although they
are of major interest due to their likely function as modi-
ﬁers of disease progression.
We assessed early symptoms other than gait ataxia
in the most frequent subtypes of SCA. To optimize
accuracy of speciﬁcations, we combined information
from both patients and close relatives in the assessment
of onset of gait ataxia. Correlations of repeat length
and disease onset were calculated for (1) occurrence of
the ﬁrst disease related symptom and (2) the onset of
gait disturbance.
PATIENTS AND METHODS
Patients were recruited in the clinical network of
EUROSCA, an international consortium funded by the
European Union for clinical and basic research in SCA
(http://www.eurosca.org). Two hundred and eighty-
seven patients were recruited in specialized ataxia clinics
in Bochum (Germany), Bonn (Germany), Brussels (Bel-
gium), Essen (Germany), Innsbruck (Austria), Milan
(Italy), Naples (Italy), Nijmegen (The Netherlands),
Paris (France), Pec (Hungary), Tu¨bingen (Germany),
and Warsaw (Poland) including 78 patients with SCA1,
97 patients with SCA2, 62 with SCA3, and 50 with
SCA6. Data on age, disease severity as assessed by the
scale for the assessment and rating of ataxia (SARA14),
and CAG repeat length are given in Table 1. Addition-
ally, 122 age- and sex-matched control subjects without
a history of neurological disease were interviewed for
symptoms that may occur early in SCA. All patients and
controls gave their written informed consent prior to
inclusion. The study was approved by the Ethics Com-
mittees of the participating centers.
Structured interviews were performed with patients
and their close relatives concerning the year of onset
of permanent gait disturbance, double vision, reduced
visual acuity, dysarthria, frequent throat clearing
reﬂecting early dysphagia, problems with hand writing,
episodic vertigo, neuropathic symptoms like weakness
or sensory complaints, cramps, restless legs syndrome,
sleep disturbances, or urinary urgency (Appendix).
TABLE 1. Biographic, genetic, and clinical data of patients included in this study
Whole cohort N 5 287 SCA1 N 5 78 SCA2 N 5 97 SCA3 N 5 62 SCA6 N 5 50
Age at examination (yr) 50.0 6 14.0 (18–84) 45.6 6 12.4 (25–76) 47.2 6 13.7 (18–84) 48.8 6 12.5 (24–72) 63.6 6 10.2 (38–83)
Age at onset of gait
ataxia (yr)
39 6 13 (7–77) 37 6 11 (16–66) 35 6 12 (7–66) 38 6 11 (18–60) 54 6 11 (34–77)
Disease duration (yr) 10.1 6 6.1 (1–33) 8.8 6 5.2 (1–22) 11.1 6 6.4 (1–30) 10.4 6 6.0 (1–25) 9.9 6 6.5 (1–33)
Sex (male/female) 150/137 49/29 42/55 32/30 27/23
SARA 14.9 6 7.9 (0–40) 15.8 6 9.4 (2–40) 15.6 6 7.5 (2–36) 13.9 6 8.1 (0–35.5) 13.6 6 5.8 (1–31)
CAG expanded NA 47 6 5 (39–62) 39 6 3 (33–47) 68 6 4 (56–75) 22 6 1 (22–28)
CAG normal NA 30 6 2 (27–36) 22 6 2 (20–33) 21 6 5 (14–34) 13 6 1 (8–14)
Disease duration is given as years with gait disturbance as ﬁxed by the patients after discussion with their relatives. Higher SARA sum scores
indicate more severe disease.14 Data are presented as mean 6 standard deviation and range (in parenthesis).
NA, not applicable.
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Additionally, we asked for other early symptoms that
may be related to SCA from the patient’s point of
view. In case of incongruent information, we asked
patients to discuss these differences with their relatives.
Ultimately, the year of onset of symptoms was ﬁxed
by the patients.
CAG repeat length was analyzed in DNA extracted
from EDTA blood samples. DNA was available from
259 patients (SCA1: 73, SCA2: 87, SCA3: 53, SCA6:
46). To optimize comparability of repeat lengths, all
analyses were performed in the same lab (Human
Genetics, Tu¨bingen). A multiplex PCR assay (described
in Ref. 15) was further optimized for robust ampliﬁca-
tion of all SCA mutations in one PCR assay: Genomic
DNA of 250 to 500 ng was used per PCR reaction.
Primer sequences, PCR conditions, and details of frag-
ment analysis are provided on request. As CAG repeats
do not perfectly result in a 3-bp spacing, expected frag-
ment lengths were compared with known (sequenced)
genotype standards and the allele calling was adapted
accordingly.
Statistics
To test whether the reported onset of permanent gait
disturbance varies between patients and relatives, a
paired Student’s t-test was performed. Correlations
between quantitative variables were assessed using
Pearson’s correlation coefﬁcient. Differences for quan-
titative variables between genotypes were compared
using ANOVA with pairwise comparisons after a sig-
niﬁcant global ANOVA (Tukey-Kramer correction of
P-value) except for the delay between early symptom
and gait ataxia that were compared using a Kruskal–
Wallis test. Frequency of symptoms in patients and
controls are compared using a Fisher’s Exact Test with
adjustment for age (year of birth) and sex (logistic
regression). Correlations between repeat length and
other variables were performed after exclusion of
patients with extreme numbers of CAG repeats deﬁned
as follows: expanded alleles SCA6 ‡ 28 CAG (1
patient); normal alleles SCA1 ‡ 33 CAG (3 patients),
SCA2 ‡ 27 CAG (2 patients), SCA3 ‡ 33 CAG (2
patients), and SCA6  8 CAG (1 patient). All tests
were performed two-sided. P < 0.05 was considered
signiﬁcant. Statistical analyses were performed using
SAS 9.1 (SAS Institute, Cary, NC).
RESULTS
Data about onset of permanent gait disturbance var-
ied frequently (44%) between SCA patients and their
relatives for 1 year or more. In 8.5% of patient-relative
pairs these differences exceeded 5 years. SCA2
patients gave a later year of onset compared to their
relatives (1.3 years 6 4.8), whereas SCA3 patients
recalled earlier onset than relatives (21.1 years 6 2.7;
SCA2 and SCA3: ANOVA with Tukey Kramer adjust-
ment for pairwise comparisons, P < 0.002). In their
ﬁnal decision, 17.4% of patients changed their appraisal
about onset of permanent gait difﬁculties in favor of
their relatives’ estimation. Differences between patients
and care givers increased with longstanding disease
(r 5 0.33, P < 0.0001; Pearson’s correlation co-
efﬁcient) but not with disease severity as assessed by
SARA (r 5 0.05, P 5 0.46).
Gait difﬁculty was reported as the initial symptom
in two-thirds (66%) of all SCA patients. Symptoms
preceding gait ataxia were in the order of frequency
cramps (9%), dysarthria (5%), sleep disturbance (5%),
double vision (4%), problems with hand writing (4%),
episodic vertigo (4%), neuropathic symptoms like
weakness or sensory complaints (3%), restless legs
syndrome (3%), urinary urgency (3%), reduced visual
acuity (2%), frequent throat clearing suggesting begin-
ning dysphagia (1%), and other symptoms preceding
gait disturbance (1%). In comparison to the control
group, only double vision, dysarthria, problems with
hand writing, and episodic vertigo occurred more fre-
quently in SCA patients (Table 2). Restricted to these
items, 12% of SCA1, 13% of SCA2, 15% of SCA3,
and 24% of SCA6 patients started the disease with
other symptoms but gait ataxia. Episodic vertigo was
especially frequent as initial symptom in SCA6
patients when compared with other SCA subtypes
(12.2% vs. 1.6–2.6%; P < 0.03; Fisher’s Exact Test).
Frequency of other early signs did not differ between
SCA genotypes.
Double vision occurred up to 8 years before gait dis-
turbance in SCA1, up to 23 years in SCA2, 16 years in
SCA3, and 35 years in SCA6 (median 6 years). Epi-
sodic vertigo preceded gait ataxia by up to 10 years in
SCA1, 1 year in SCA2, 2 years in SCA3, and 15 years
in SCA6 (median 4 years). Four percent of SCA
patients experienced these symptoms more than 5 years
before onset of gait ataxia (5% in SCA1, 3% in SCA2,
2% in SCA3, and 8% in SCA6). Dysarthria and prob-
lems with hand writing were reported not more than
5 years before onset of gait ataxia.
CAG repeat length in the expanded allele was re-
sponsible for about 60% of variability in age at onset
of gait ataxia in SCA1 and SCA2, for about 25% in
SCA3, and about 20% in SCA6. No major differences
in correlation with repeat length were observed when
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information about age of onset was provided by
patients or by their relatives or after discussion of both
(Table 3). Under the hypothesis that long disease dura-
tion may hamper accuracy of memory concerning
onset of the disease, we repeated correlations after
exclusion of patients with the disease for more than 10
years. This improved correlations especially in SCA3
and SCA6 (Table 3, Fig. 1A–D). Exclusion of patients
with more severe disease (SARA sum score above 20
points14) had a similar effect. Consideration of nongait
symptoms did not further improve the predictive value
of CAG repeat for age of onset (Table 3). No effect of
normal alleles on age at onset was found.
We tested the hypothesis that initial symptoms of
SCA may be determined by repeat length. No group
differences in number of CAG repeats were found con-
cerning ﬁrst symptoms in any SCA genotype (Wil-
coxon two-sample test).
DISCUSSION
This systematic study on disease onset in SCA dem-
onstrated that gait ataxia is the initial complaint in
only two-thirds of patients. When rather unspeciﬁc
symptoms like cramps, restless legs, and sleep disturb-
ance were excluded still 16% of SCA patients report
other problems than gait as the earliest symptom. Espe-
cially, diplopia and episodic vertigo but also dysrthria
and clumsiness occurred prior to onset of gait ataxia.
None of the early clinical signs had speciﬁcity for a
certain SCA subtype but episodic vertigo was more
common in SCA6. This reﬂects the close relationship
of SCA6 and episodic ataxia type 2 (EA2), both of
which are caused by mutations in the a1A-subunit
of the voltage-gated neuronal calcium channel.16
Although patients with EA2 frequently develop cere-
bellar atrophy on MRI and permanent gait ataxia after
longstanding disease, episodic ataxia has rarely been
reported in patients with SCA6.17–21
Detection of early signs is of major importance for
consecutive treatment management. If disease modulat-
ing compounds become available, they may be most
efﬁcient when introduced to patients in early stages of
the disease. On the other hand, treatment before dis-
ease onset may not be advisable in drugs with potential
side effects. Thus, reliable diagnosis of disease onset is
a major challenge and recognition of nonataxia symp-
toms might be a promising approach.
TABLE 2. Symptoms preceding gait abnormalities in SCA
Co All SCA SCA1 SCA2 SCA3 SCA6
Double vision – 4.3 1.3 3.2 10.0**,a 4.2
Reduced visual acuity 4.1 2.1 5.1 1 – 2
Dysarthria – 4.7 2.6 5.6* 3.3 8.2*
Frequent throat clearing – 1.4 2.6 1.1 1.6 –
Problems with hand writing – 4 5.3 5.6* 1.7 2.1
Episodic vertigo 1.6 3.9 2.6 2.1 1.6 12.2*
Neuropathic symptoms 4.1 2.9 4 – 4.8 4.1
Cramps 8.2 8.9 11.5 9.9 4.9 8
Restless legs syndrome 6.3 2.8 5.3 2.1 1.6 2
Sleep disturbances 9.0 4.7 2.6 2.2* 5 12.5
Urinary urgency 1.6 2.8 3.9 3.2 1.6 2
Other preceding symptoms 0.7 1.3 – 1.7 –
Proportion of patients (%) who reported onset of the respective symptom prior to gait ataxia.
*P < 0.05; **P < 0.01 (comparison of SCA vs. control group; Fisher’s Exact Test after adjustment for age and sex).
aP < 0.05 (comparison to SCA1, 2, and 3).
TABLE 3. Correlation of CAG repeat length
and age of onset









Patients onlya 57*** 59*** 27*** 19**
Relatives onlya 51*** 61*** 24*** 17*
Patients 1 relativesa 57*** 60*** 26*** 20**
Patients 1 relatives
1 duration < 10 yra
64*** 67*** 46*** 41***
Patients 1 relatives
1 SARA < 20a
53*** 67*** 47*** 21**
Occurrence of diplopia,
dysarthria, clumsiness,
episodic vertigo, or gait
disturbance
55*** 54*** 25** 2
Percentages to which repeat length determined age of onset are
given for different deﬁnitions of disease onset.
*P < 0.05; **P < 0.01; ***P < 0.001.
aOnset of progressive gait ataxia.
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Our results suggest that ﬁrst symptoms may occur a
decade or more before the onset of gait instability. The
list of symptoms analyzed in this study is by no means
complete but had to be restricted to problems that
could be remembered with acceptable accuracy also
after many years. In this respect, it is important to note
that not only patients in late stages of the disease
described early symptoms many years before onset of
gait difﬁculties, but also patients with short disease du-
ration and low SARA scores indicating less advanced
disease reported problems such as diplopia to precede
gait ataxia for up to 15 years.
Assessment of disease onset was poorly standardized
in former studies.4,5 In this study, the view of close
relatives concerning the onset of gait ataxia differed
from the patient’s report in 17% of cases with a span
of 5 to 20 years with mean differences between 1.2
and 4.5 years depending on the genotype. The largest
differences between patients and relatives were
observed when disease duration exceeded 10 years.
These ﬁndings underline the importance of standar-
dized assessment to yield most reliable results and
stress the necessity of prospective studies of disease
onset in SCA. Why SCA3 patients recognized onset of
gait ataxia about 1 year earlier than their relatives,
whereas SCA2 patients dated the beginning of gait
difﬁculties 1 year later than their relatives remains
unclear. It would be reasonable to expect that patients
feel changes in gait stability before it becomes obvious
from outside. Whether cognitive changes that are more
pronounced in SCA2 than in other subtypes22,23 con-
tribute to the shift in recognition or memory in SCA2
FIG. 1. Linear regression analysis of age at onset and length of expanded CAG repeat. Onset has been deﬁned as beginning of progressive gait
ataxia. Patients with disease durations of more than 10 years have been excluded.
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has to be assessed in prospective studies including neu-
ropsychological testing.
Our data conﬁrm that CAG repeat length can only par-
tially explain variability in age of onset of SCA. Our
data revealed the closest correlation with CAG repeat
length when (1) onset is deﬁned by beginning of perma-
nent gait disturbance and (2) patients with longstanding
disease were excluded. Correlation did not improve fur-
ther when nongait symptoms were taken into account.
Interviews with caregivers did not improve correlation of
onset age and CAG repeat length, although dates for
onset varied substantially between patients and relatives.
Under all conditions, CAG repeat length explained less
than 50% of variability in age of onset in SCA3 and
SCA6. In SCA6, the inﬂuence of repeat length may be
masked by the rather uniform size of the expanded allele
(22 CAG in 74% of SCA6 patients). However, our data
show that onset variability in all SCA subtypes is driven
by other genetic or environmental factors that remain to
be identiﬁed. Given the enormous variability in onset
data depending on the assessment strategy, prospective
studies with standardized evaluation procedures of disease
onset are necessary to identify disease modiﬁers that
have minor effects than repeat length in expanded alleles.
Recent progress in the understanding of disease mech-
anisms in polyglutamine disorders and promising results
in animal models24–26 offer chances for clinical trials of
potentially disease modifying compounds in the near
future. If such compounds aim to delay disease, a precise
prediction of onset age is warranted. This may not be
possible for individual patients but is feasible for larger
cohorts. To this end, recognition of early symptoms that
may develop before the onset of gait ataxia is mandatory
and will require prospective studies.
Acknowledgments: This study has been funded by the Eu-
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APPENDIX
Instructions for the Structured Interview of Early
Symptoms in SCA
Deﬁnition of Age at Onset
c Onset is deﬁned as the beginning of permanent and
progressive gait instability.
c Patients are asked for the onset of permanent and
progressive gait instability. Orientation is provided
from biography by asking for ataxia at major events
in former years (e.g., 50th birthday party). Addition-
ally, patient is confronted with onset data mentioned
in former records if available.
c Close relatives are asked in the same manner. If no
relatives accompany the patient call spouses or chil-
dren.
c Then, ask the patient to settle potential discrepancies
with the statement of his/her relatives for ﬁnal deter-
mination of age at onset.
c Afterward, ask the patient for onset of gait ataxia in
parents, sibs, and children. List these statements.
Early Symptoms of SCA
c After determination of onset of permanent gait insta-
bility ask the patient and his/her relatives for other
symptoms of SCA that may have preceded the onset
of gait ataxia. List spontaneous recall.
c Then, offer a list of potential early symptoms of
SCA like
 Double vision
 Reduced visual acuity (If present, verify that
this is due to retinopathy or optic atrophy)
 Dysarthria
 Problems with hand writing
 Episodic vertigo
 Weakness or sensory complaints related to pe-
ripheral neuropathy
 Restless legs syndrome
 Sleep disturbance (specify if possible)
 Urinary urgency or incontinence.
c Ask for the year of ﬁrst occurrence of symptoms
that preceded gait ataxia.
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